Please assess the completion status of the following clinical trial:

Trial Title: A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 1: Healthy male or female adults 50 to 64 years of age with no history of pneumococcal vaccination~* Stage 2: Healthy male or female adults 65 to 85 years of age previously vaccinated with Prevnar 13 \>= 2 months prior to investigational product administration~Exclusion Criteria:~* Stage 1: Vaccination within 12 months before investigational product administration with diphtheria-, pertussis-, or tetanus-containing vaccine~* Stage 2: Previous vaccination with any pneumococcal vaccine other than a single prior dose of Prevnar 13

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Stage 1 multivalent (ages 50-64 years) (Type: EXPERIMENTAL): multivalent
- Stage 1 Tdap (ages 50-64 years) (Type: ACTIVE_COMPARATOR): Tdap
- Stage 2 multivalent (ages 65-85 years) (Type: EXPERIMENTAL): multivalent
- Stage 2 polysaccharide (ages 65-85 years) (Type: ACTIVE_COMPARATOR): polysaccharide

Based on this trial design, predict the completion outcome and termination type (if applicable).